Abstract
A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have